ALK Inhibitor Offers Hope for Rare, Aggressive Tumor Types
— Phase II trial reveals brigatinib surpasses historical benchmarks by reducing 10% of targeted tumors A Phase II platform trial presented promising findings for patients suffering from NF2-related schwannomatosis with advancing tumors. The ALK inhibitor brigatinib (Alunbrig) demonstrated potential across various tumor types, showing measurable tumor shrinkage and enhancements in hearing, along with improvements in other clinical parameters. Among 40 individuals diagnosed with either vestibular
269 likes
10 969 views
